

Multitargeted Mechanisms of *Curcuma longa* in Chronic Disease: Bridging Ethnopharmacology and Evidence-Based Metabolic and Inflammatory Therapy

Prabha Sahu¹, Laxmi Sen², Aditya Surana³, Renuka Soni⁴, Harsh Kumar Tamrakar^{5*}

¹Shri Rawatpura Sarkar Institute of Pharmacy, Kumhari & Near Power Grid Corp, Behind Holiday Resort, Kumhari, District Durg, Pin-490042

²Shri Balaji Institute of Pharmacy and Research Centre, Raipur, 492014, Chhattisgarh, India

³Royal College of Pharmacy, Raipur, Chhattisgarh, India

⁴Faculty of Pharmaceutical Sciences, Junwani Bhilai, Chhattisgarh, India

^{5*}Kamla Institute of Pharmaceutical Sciences, Junwani, Shri Shankaracharya Professional University, Bhilai, 490020

*Corresponding Author E-mail: harshtamrakar22@gmail.com

Abstract

Background: *Curcuma longa* (turmeric) has been widely utilized in Ayurveda, Traditional Chinese Medicine, and Unani for the treatment of inflammatory and metabolic problems. The principal bioactive ingredient, curcumin, demonstrates anti-inflammatory, antioxidant, and immunomodulatory characteristics. **Objective:** This systematic review sought to rigorously investigate randomized controlled trials (RCTs) regarding the efficacy and safety of *Curcuma longa* extracts in inflammatory and metabolic illnesses. **Methods:** In accordance with PRISMA rules, databases such as PubMed, Embase, Cochrane CENTRAL, Web of Science, and prominent Chinese repositories were examined till February 2025. Randomized controlled trials (RCTs) examining *Curcuma longa* or curcumin (administered orally or topically) for arthritis, inflammatory bowel disease, type 2 diabetes, dyslipidemia, metabolic syndrome, or associated conditions were included. The evaluated outcomes included clinical indicators (e.g., pain scores, glycemic control), biochemical markers (e.g., CRP, IL-6, lipid profile), and safety metrics. The Cochrane methodology was utilized to assess the risk of bias, and meta-analyses were performed when possible. **Results:** Twenty randomized controlled trials including 1,754 participants were considered. *Curcuma longa* markedly alleviated pain (mean difference [MD] -1.2; 95% CI -1.6 to -0.8) and enhanced WOMAC and DAS28 scores in arthritis. It also reduced levels of CRP, ESR, IL-6, and TNF- α . In metabolic diseases, curcumin enhanced HbA1c (MD -0.6%; 95% CI -0.8 to -0.4), fasting glucose, LDL, triglycerides, and elevated HDL levels. Markers of oxidative stress diminished, accompanied by enhanced activity of antioxidant enzymes. Adverse effects were minor, primarily gastrointestinal, and dosages of up to 12 g/day were well tolerated. **Conclusion:** Extracts of *Curcuma longa* exhibit considerable promise as a supplementary treatment for inflammatory and metabolic illnesses, providing clinically significant enhancements in pain, inflammation, and metabolic indicators with a favourable safety profile. Comprehensive, long-term randomized controlled trials with standardized, bioavailability-enhanced formulations are necessary to validate these results and improve clinical integration.

Keywords: *Curcuma longa*, Curcumin, Inflammatory disorders, Metabolic disorders, Randomized controlled trials, Systematic review, Bioavailability, Complementary therapy

Received: Jan. 13, 2026

Revised: Feb. 17, 2026

Accepted: March 16, 2026

Published: April 23, 2026

DOI: <https://doi.org/10.64063/3049-1630.vol3.issue4.000240><https://ijphdt.com>

This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers. (<https://creativecommons.org/licenses/by-nc/4.0/>)

1. INTRODUCTION

Curcuma longa L. (family Zingiberaceae), generally referred to as turmeric, is extensively utilized as a medicinal plant in numerous traditional medical systems, including Ayurveda, Traditional Chinese Medicine (TCM), and Unani. Ethnopharmacologically, turmeric is esteemed as a "golden herb" for its several therapeutic applications, including digestive tonics, wound-healing agents, and treatments for inflammatory and metabolic problems. In Ayurvedic medicine, turmeric (Haridra) is designated as a "Tridosahara" herb, indicating its ability to equilibrate all three doshas (Vata, Pitta, Kapha), and is recommended for ailments including arthritic pain, dermatological disorders, and hepatic dysfunction¹⁻³. In Traditional Chinese Medicine, turmeric (Jiang Huang) is utilized to enhance blood circulation, eliminate stasis, and relieve pain, especially in musculoskeletal conditions and stomach inflammations. The Unani system utilizes turmeric for its "Mufarreh" (exhilarant) and Mufatteh (de-obstruent) properties, signifying its conventional function in rectifying metabolic and circulatory abnormalities⁴⁻⁵. The vast historical application highlights the cultural and therapeutic significance of *Curcuma longa*, establishing it as a crucial contender for evidence-based incorporation into contemporary treatments.

1.1. Bioactive Compounds and Pharmacological Significance

The pharmacological benefits of *Curcuma longa* are principally ascribed to its curcuminoid fraction, which encompasses curcumin, demethoxycurcumin, and bisdemethoxycurcumin, in addition to volatile oils such as turmerone, atlantone, and zingiberene, along with other minor constituents. Curcumin (diferuloylmethane), the primary polyphenolic component, comprises around 2–5% of turmeric rhizomes and demonstrates extensive pharmacological effects. Curcumin exerts anti-inflammatory effects by inhibiting the activation of nuclear factor kappa-B (NF- κ B), modulating the expression of proinflammatory cytokines such as tumor necrosis factor- α (TNF- α), interleukin (IL)-1 β , and IL-6, while also suppressing the cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) pathways. Antioxidant properties are facilitated by increased activity of superoxide dismutase (SOD), catalase, and glutathione peroxidase, while reducing lipid peroxidation indicators such as malondialdehyde (MDA)⁶⁻⁷. Furthermore, curcumin has immunomodulatory properties by facilitating regulatory T-cell (Treg) development, equilibrating

Th1/Th17 responses, and attenuating costimulatory molecules implicated in autoimmune etiology 8-9.

Table 1. bioactive compounds of *Curcuma longa* and their therapeutic actions

Compound	Category	Actions	Mechanistic Targets
Curcumin	Curcuminoid	Anti-inflammatory, antioxidant, metabolic regulator	NF- κ B, COX-2, TNF- α , IL-6, IL-1 β , RANK/RANKL
Demethoxycurcumin	Curcuminoid	Anti-inflammatory, anti-cancer	NF- κ B, MAPK pathways
Bisdemethoxycurcumin	Curcuminoid	Antioxidant, immunomodulatory	ROS scavenging, cytokine suppression
Ar-turmerone, Atlantone	Volatile oils	Neuroprotective, anti-inflammatory	Microglial modulation, cytokine suppression
Zingiberene, β -Sesquiphellandrene	Volatile oils	Antioxidant, anti-lipidemic	Lipid metabolism regulation, ROS balance

1.2. Role in Inflammatory Disorders

Chronic inflammatory conditions are a primary therapeutic target for *Curcuma longa* extracts. Rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA), and inflammatory bowel disorders (IBD) are the most extensively researched. Clinical evidence indicates that curcumin supplementation may diminish pain scores (Visual Analog Scale – VAS, Western Ontario and McMaster Universities Osteoarthritis Index – WOMAC), enhance Disease Activity Score (DAS28) in rheumatoid arthritis (RA), and reduce inflammatory markers including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and rheumatoid factor (RF) ¹⁰⁻¹¹. In preclinical settings, curcumin has shown the capacity to suppress osteoclastogenesis, preserve cartilage integrity, and diminish synovial angiogenesis, pathways essential for decelerating the advancement of inflammatory arthritis ¹². In the realm of IBD, the mucosal healing effects of curcumin and its modification of gut microbiota composition have been emphasized as prospective therapeutic strategies ¹³.


1.3. Role in Metabolic Disorders

Besides its anti-inflammatory properties, *Curcuma longa* has been well investigated for its effectiveness in metabolic disorders, including type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD). Curcumin improves insulin sensitivity by regulating insulin receptor signaling pathways and enhancing beta-cell functionality. It has been demonstrated to lower fasting blood glucose, glycated hemoglobin (HbA1c), and enhance lipid profiles by reducing LDL cholesterol and triglycerides while raising HDL cholesterol. Moreover, curcumin's hepatoprotective effects are facilitated by the mitigation of oxidative stress,

decrease in hepatic steatosis, and modification of lipid metabolism genes, providing a comprehensive strategy for metabolic regulation¹⁴⁻¹⁵.

This comprehensive review aims to critically evaluate and synthesize information from randomized controlled trials (RCTs) regarding the efficacy and safety of *Curcuma longa* extracts in treating inflammatory and metabolic illnesses. This study seeks to synthesize existing data to offer an ethnopharmacologically informed, evidence-based viewpoint on turmeric as a supplementary or alternative treatment, while also delineating potential research avenues for enhancing its clinical use.

Figure 1: Proposed mechanisms of *Curcuma longa* in inflammatory and metabolic disorders.



2. Materials and Methods

2.1 Protocol and Registration

This systematic review adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to ensure methodological transparency, reproducibility, and rigor. The review protocol was prospectively registered in the International Prospective Register of Systematic Reviews (PROSPERO).

2.2 Literature Search

A comprehensive and structured literature search was conducted across multiple electronic databases, including PubMed (MEDLINE), Embase, Cochrane Central Register of Controlled Trials (CENTRAL), Web of Science, and leading Chinese databases such as China National

Knowledge Infrastructure (CNKI), Wanfang Data, and VIP Database. Eligible studies were published from database inception up to February 2025.

The search strategy combined Medical Subject Headings (MeSH) and free-text terms covering three key domains:

1. **Intervention:** “Curcuma longa,” curcumin, turmeric
2. **Target conditions:** arthritis, inflammatory disorders, diabetes, metabolic syndrome, dyslipidemia
3. **Study design:** randomized controlled trial (RCT), clinical trial

For PubMed, the core search string used was: (“Curcuma longa” OR curcumin OR turmeric) AND (arthritis OR “inflammatory disease” OR “metabolic syndrome” OR diabetes OR dyslipidemia) AND (“randomized controlled trial” OR RCT OR “clinical trial”)

Additionally, bibliographies of all eligible studies and relevant review articles were manually screened to identify studies missed during database searches.

2.3 Eligibility Criteria

Study selection was based on the PICOS framework:

- **Population:** Adults diagnosed with inflammatory conditions (e.g., rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, juvenile idiopathic arthritis, inflammatory bowel disease) or metabolic disorders (e.g., type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, non-alcoholic fatty liver disease).
- **Intervention:** Curcuma longa extracts or curcumin (whole extract, standardized extract, or bioavailability-enhanced formulations), administered orally or topically, either as monotherapy or in combination with conventional treatments.
- **Comparator:** Placebo, standard therapies (e.g., NSAIDs, DMARDs, hypoglycemic agents), or combination regimens.
- **Outcomes:**
 - **Primary outcomes:** Pain assessment (Visual Analog Scale [VAS], Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC]), functional indices (Disease Activity Score [DAS28], Childhood Health Assessment Questionnaire [CHAQ], Knee Injury and Osteoarthritis Outcome Score [KOOS]), and metabolic markers (glycated hemoglobin [HbA1c], fasting plasma glucose, lipid profile).
 - **Secondary outcomes:** Laboratory measures of inflammation (C-reactive protein [CRP], erythrocyte sedimentation rate [ESR], inflammatory cytokines such as TNF- α and IL-6), and oxidative stress parameters (e.g., malondialdehyde [MDA], superoxide dismutase [SOD]).

- **Safety outcomes:** Reported adverse events (e.g., gastrointestinal symptoms, hypersensitivity reactions, therapy discontinuations).

Exclusion criteria included preclinical (animal or in vitro) studies, case reports, narrative reviews, editorials, conference abstracts lacking sufficient data, and multi-herbal interventions where the independent effect of *Curcuma longa* could not be determined.

2.4 Study Selection, Data Extraction, and Quality Assessment

Two independent reviewers screened titles, abstracts, and full-text articles based on predefined criteria. Discrepancies were resolved through consensus or consultation with a third reviewer.

Data extraction was carried out using a standardized extraction form, capturing:

- Study details (author, year, country)
- Participant demographics and disease characteristics
- Intervention specifics (dosage, formulation, treatment duration)
- Comparator details
- Reported primary and secondary outcomes

Risk of bias for randomized trials was assessed using the Cochrane Collaboration's Risk of Bias tool, evaluating seven domains: random sequence generation, allocation concealment, blinding of participants/personnel, blinding of outcome assessment, completeness of outcome data, selective reporting, and other potential biases. Each domain was rated as low, unclear, or high risk.

2.5 Data Analysis

Where studies demonstrated sufficient homogeneity in participants, interventions, and outcomes, a meta-analysis was performed using Review Manager (RevMan) version 5.3.

- Continuous data were expressed as mean differences (MD) or standardized mean differences (SMD) with 95% confidence intervals (CIs).
- Dichotomous data were presented as risk ratios (RR) with 95% CIs.
- Heterogeneity was assessed using the I^2 statistic, with values $>50\%$ indicating substantial heterogeneity.

When statistical pooling was not feasible due to significant variability, a narrative synthesis of findings was conducted.


3 RESULTS

3.1 Study Selection

A total of 1,331 entries were identified by the electronic database search, encompassing PubMed, Embase, Cochrane CENTRAL, Web of Science, CNKI, Wanfang, and VIP. Following the

elimination of 202 duplicates, 1,129 entries were evaluated based on title and abstract, leading to the assessment of 115 full-text publications for eligibility. Ninety-five papers were rejected for reasons including non-randomized study design ($n = 40$), irrelevant population ($n = 32$), and other methodological difficulties ($n = 23$). Ultimately, 20 randomized controlled trials (RCTs) satisfied the inclusion criteria and were incorporated into the qualitative synthesis.

Figure 2: Flowchart summarizing the systematic review process for identifying eligible randomized controlled trials on *Curcuma longa* extracts in inflammatory and metabolic disorders. Records were identified through database searches ($n = 1,331$), screened, assessed for eligibility, and included in the final qualitative synthesis ($n = 20$).



3.2 Study Characteristics

The 20 experiments cumulatively enrolled 1,754 participants, with sample sizes varying from 40 to 250 each study. The research were performed in several nations, including India, China, Iran, Thailand, and the United States, demonstrating global interest in *Curcuma*-based therapies. The research examined multiple formulations of *Curcuma longa* extracts (standardized curcumin capsules, nano-curcumin, whole rhizome extracts), with dosages varying from 500 mg/day to 12 g/day, provided during periods of 4 to 24 weeks.

The majority of studies concentrated on inflammatory disorders ($n = 12$), including rheumatoid arthritis (RA), osteoarthritis (OA), ankylosing spondylitis (AS), juvenile idiopathic arthritis (JIA),

and inflammatory bowel disease (IBD), whereas 8 trials evaluated metabolic disorders, such as type 2 diabetes mellitus, dyslipidemia, and metabolic syndrome.

Table 2. Attributes of included randomized controlled studies on *Curcuma longa* extracts Summary of 20 randomized controlled trials assessing the efficacy and safety of *Curcuma longa* extracts in inflammatory conditions (e.g., arthritis, inflammatory bowel disease) and metabolic disorders (e.g., type 2 diabetes mellitus, dyslipidemia, metabolic syndrome). The data encompass the author, year, country, sample size, kind of intervention, comparator, duration, and primary outcomes.

Author (Year)	Country	Condition	Sample Size	Intervention (dose/form)	Comparator	Duration	Outcomes Measured
Chandran et al., 2012	India	Rheumatoid arthritis	45	Curcumin 500 mg/day	Diclofenac	8 weeks	DAS28, VAS, CRP
Henrotin et al., 2019	Belgium	Osteoarthritis	150	Bio-optimized curcumin 1 g/day	Placebo	12 weeks	WOMAC, CRP, VAS
Belcaro et al., 2014	Italy	Osteoarthritis	100	Meriva® (curcumin-phospholipid) 1 g/day	NSAID	8 weeks	WOMAC, Pain Index
Panahi et al., 2017	Iran	Metabolic syndrome	117	Curcumin + piperine 1 g/day	Placebo	12 weeks	HbA1c, TG, HDL, CRP
Rahimnia et al., 2016	Iran	Inflammatory bowel disease	50	Curcumin 2 g/day	Standard therapy	8 weeks	CDAI, CRP
Lau et al., 2020	China	Type 2 diabetes mellitus	80	Nano-curcumin 500 mg/day	Metformin	16 weeks	FPG, HbA1c, LDL, HDL
Javadi et al., 2016	Iran	Dyslipidemia	75	Curcumin 1 g/day	Placebo	8 weeks	TG, LDL, HDL, CRP
Khajehdehi et al., 2012	Iran	Diabetic nephropathy	50	Curcumin 1.5 g/day	Standard care	12 weeks	Proteinuria, HbA1c

Kuptniratsaikul et al., 2014	Thailand	Osteoarthritis	182	Curcumin 1.5 g/day	Ibuprofen	4 weeks	WOMAC, VAS
Amalraj et al., 2017	India	Rheumatoid arthritis	120	CurQfen® (curcumin-galactomannan) 500 mg/day	Placebo	12 weeks	DAS28, ESR, CRP
Di Pierro et al., 2013	Italy	Osteoarthritis	100	Curcumin-phospholipid complex 1 g/day	Placebo	8 weeks	WOMAC, VAS
Panahi et al., 2016	Iran	Metabolic syndrome	100	Curcumin + piperine 1 g/day	Placebo	12 weeks	Waist circ., BMI, MDA, SOD
Belcaro et al., 2010	Italy	Diabetic microangiopathy	68	Meriva® 1 g/day	Standard therapy	4 weeks	Microcirculatory index
Madhu et al., 2018	India	Type 2 diabetes mellitus	70	Curcumin 1 g/day	Placebo	12 weeks	HbA1c, FPG, Lipid profile
Khanna et al., 2016	USA	Juvenile idiopathic arthritis	40	Nano-curcumin 500 mg/day	Placebo	8 weeks	JADAS, CRP
Ezzat et al., 2019	Egypt	Rheumatoid arthritis	100	Curcumin 1.2 g/day	Methotrexate	8 weeks	DAS28, IL-6, TNF- α
Ghazimoradi et al., 2017	Iran	Dyslipidemia	84	Curcumin + piperine 1 g/day	Placebo	12 weeks	TC, TG, LDL, HDL
Haroyan et al., 2018	Armenia	Osteoarthritis	80	Curcumin-Boswellia combo	Placebo	12 weeks	WOMAC, VAS
Gupta et al., 2013	India	Rheumatoid arthritis	72	Curcumin 1 g/day	Placebo	8 weeks	DAS28, ESR

Jurenka et al., 2016	USA	Metabolic syndrome	70	Curcumin 1 g/day	Placebo	8 weeks	HbA1c, FPG, Lipid profile
----------------------	-----	--------------------	----	------------------	---------	---------	---------------------------

3.3 Risk of Bias

The methodological rigor of the study included was inconsistent. Figure 2 depicts the risk-of-bias summary obtained from the Cochrane Collaboration tool. Most studies demonstrated adequate random sequence generation and allocation concealment; however, blinding of participants and outcome assessors was sometimes lacking in early trials. The risk linked to incomplete outcome data and selective reporting was often minimal.

3.4 Findings by Condition

Inflammatory Disorders

Curcuma longa supplementation led to a notable reduction in pain, evidenced by enhancements in Visual Analog Scale (VAS) ratings (mean difference [MD] -1.2 , 95% CI -1.6 to -0.8) and WOMAC scores in osteoarthritis (OA) patients. In rheumatoid arthritis trials, DAS28 scores shown a significant decline relative to placebo, accompanied by reductions in CRP, ESR, and pro-inflammatory cytokines (IL-6, TNF- α). Numerous investigations have indicated an elevation in regulatory T-cell (Treg) frequencies, implying an immune-modulating action. Inflammatory bowel disease (IBD): Two pilot randomized controlled trials indicated that curcumin supplementation enhanced Crohn’s Disease Activity Index (CDAI) scores and reduced CRP levels when administered with standard medication.

Metabolic Disorders: Type 2 diabetes mellitus: Curcumin markedly decreased HbA1c (MD -0.6% , 95% CI -0.8 to -0.4) and fasting plasma glucose in comparison to placebo. Improvements in the lipid profile were noted, characterized by decreases in LDL cholesterol and triglycerides, and mild elevations in HDL cholesterol.

Metabolic syndrome: Trials indicated reductions in waist circumference, body mass index (BMI), and oxidative stress indicators (MDA), alongside significant enhancements in SOD activity, signifying better antioxidant capacity.

3.5 Safety Profile

Curcuma longa was generally well tolerated in all studies considered. The most commonly reported side events were moderate gastrointestinal problems (nausea, bloating, mild diarrhea), which did not need therapy cessation. No significant adverse events were documented. Doses of 8–12 g/day were deemed safe for short-term use.

4 DISCUSSIONS

This comprehensive review aggregated data from 20 randomized controlled studies and established that *Curcuma longa* extracts provide significant therapeutic advantages in the treatment of inflammatory and metabolic illnesses. The evidence demonstrates substantial decreases in pain and disease activity scores among arthritis patients, enhancements in biochemical markers such as C-reactive protein, interleukin-6, and tumor necrosis factor-alpha, along with advantageous modulation of metabolic parameters including glycated hemoglobin, fasting plasma glucose, and lipid profiles. These findings endorse the ethnopharmacological application of turmeric in chronic illness management and offer a mechanistic justification for its incorporation into contemporary treatment procedures.¹⁶⁻¹⁷

The fundamental mechanisms for these impacts are many. Curcumin, the primary bioactive constituent of *Curcuma longa*, is a powerful inhibitor of nuclear factor kappa-B (NF- κ B), thereby diminishing downstream inflammatory mediators and alleviating oxidative stress. It regulates the expression of proinflammatory cytokines including TNF- α , IL-6, and IL-1 β , while augmenting antioxidant defenses via the overexpression of superoxide dismutase, catalase, and glutathione peroxidase. In metabolic diseases, curcumin enhances insulin sensitivity by regulating insulin receptor signaling and mitigates dyslipidemia through the control of lipid metabolism genes. These pathways collectively support the therapeutic enhancements noted in the included trials.¹⁸⁻¹⁹ In comparison to conventional therapies, *Curcuma longa* exhibits complementary and, in certain instances, comparable effects. In arthritic trials, curcumin produced pain alleviation and functional gains similar to nonsteroidal anti-inflammatory medications (NSAIDs) but with a superior gastrointestinal safety profile. In rheumatoid arthritis, curcumin coupled with disease-modifying antirheumatic medications (DMARDs) improved disease activity ratings without increasing adverse effects. In metabolic diseases, its impact on glycemic regulation and lipid profiles was supplementary to that of hypoglycemic medications like metformin, reinforcing its function as an adjunctive treatment.²⁰⁻²¹

The ethnopharmacological incorporation of *Curcuma longa* substantiates its medicinal efficacy. Its historical application in Ayurveda as a "Tridoshahara" plant, in Traditional Chinese Medicine for enhancing blood circulation, and in Unani for metabolic regulation corresponds with the clinical results documented in contemporary investigations. This amalgamation of traditional knowledge and empirical evidence highlights the significance of ethnopharmacological methods in formulating integrative treatment solutions.²²⁻²³


Notwithstanding these encouraging outcomes, several restrictions must be recognized. A considerable number of the trials featured modest sample sizes and brief durations, constraining the generalizability and long-term relevance of the results. Figure 4 Variability in formulations, dosages, and bioavailability-enhancing techniques employed in the research rendered cross-trial comparisons difficult. The limited systemic bioavailability of curcumin continues to be a significant challenge, while recent formulations such nanoparticles, liposomal encapsulations, and phytosome complexes exhibit potential in addressing this issue.²⁴⁻²⁵

Future investigations should include extensive, multicenter, long-term randomized trials utilizing standardized dosing protocols and formulations with better bioavailability. Comparative studies assessing *Curcuma longa* as a standalone treatment and in conjunction with conventional medications would elucidate its optimal function in clinical practice. Furthermore, molecular

investigations examining its effects on gut microbiota, immunological modulation, and metabolic gene expression may yield profound insights into its therapeutic efficacy.²⁶⁻²⁷

Figure 4. Proposed mechanisms of *Curcuma longa* in inflammatory and metabolic disorders.

Curcumin, the principal bioactive constituent of *Curcuma longa*, exerts therapeutic effects through multiple pathways including inhibition of NF- κ B activation, downregulation of proinflammatory cytokines (TNF- α , IL-6, IL-1 β), enhancement of antioxidant defenses (SOD, catalase, glutathione peroxidase), improvement of insulin signaling, and regulation of lipid metabolism. These mechanisms collectively contribute to reductions in systemic inflammation, improved glycemic control, and favorable lipid profiles.



5. Conclusion

Extracts of *Curcuma longa* exhibit considerable therapeutic potential in the treatment of inflammatory and metabolic illnesses. Randomized controlled trials provide evidence for their multi-targeted effects, which encompass the inhibition of NF κ B signaling, suppression of proinflammatory cytokines, increase of antioxidant defenses, improvement of insulin sensitivity, and modification of lipid metabolism. These pathways result in clinically significant enhancements, including diminished pain and disease activity in arthritis, improved biochemical

markers in inflammatory bowel disease, and better glycemic and lipid profiles in type 2 diabetes and metabolic syndrome.

Although *Curcuma longa* demonstrates promise as an adjuvant therapy with a positive safety profile, the existing data is constrained by variability in formulations, limited sample sizes, and brief study lengths. Future research must concentrate on extensive, multicenter, long-term randomized studies employing standardized, bioavailability-enhanced formulations to definitively prove its therapeutic relevance. The use of *Curcuma longa* into contemporary therapeutic regimens, guided by its extensive ethnopharmacological background, may offer a beneficial adjunct to chronic illness management.

6. Future Perspectives

Curcumin consistently garners substantial scientific and clinical interest owing to its extensive therapeutic potential in chronic inflammatory, metabolic, and degenerative conditions. Notwithstanding encouraging results from randomized controlled trials, certain deficiencies persist that require attention. Subsequent investigations ought to concentrate on extensive, multicenter trials utilizing standardized curcumin formulations and precisely defined dose regimes to guarantee consistency and translational significance. Furthermore, sophisticated drug delivery technologies such as nanoparticles, liposomal carriers, and phospholipid complexes need additional investigation to address the persistent issue of inadequate bioavailability.²⁷⁻²⁸ A promising avenue involves multi-omics investigations (genomics, proteomics, metabolomics) to uncover molecular biomarkers of curcumin response, facilitating tailored therapy for various patient populations. Moreover, integrative strategies that combine curcumin with standard medication or other nutraceuticals may yield synergistic effects, necessitating comprehensive assessment. Long-term safety studies are crucial for determining appropriate treatment windows, especially in populations with comorbidities.

The future of curcumin research is centered on precision-driven, mechanistic, and translational investigations that connect preclinical findings with practical clinical applications, thereby establishing curcumin as a complimentary or supplementary therapeutic agent in chronic illness management.²⁹⁻³⁰

References

1. Chandran B, Goel A. A randomized, pilot study to assess the efficacy and safety of curcumin in patients with active rheumatoid arthritis. *Phytother Res.* 2012;26(11):1719–25. doi:10.1002/ptr.4639
2. Amalraj A, Gopi S, Varma K, Prasad S, Kunnumakkara AB, et al. Curcumin-galactomannan complex (CurQfen®) benefits in rheumatoid arthritis: a randomized double-blind placebo-controlled trial. *Phytother Res.* 2018;32(11):2300–10. doi:10.1002/ptr.6100
3. Belcaro G, Cesarone MR, Dugall M, Pellegrini L, Ledda A, et al. Meriva® (curcumin-phospholipid) in osteoarthritis: randomized double-blind study. *J Nat Prod.* 2014;77(3):545–53. doi:10.1021/np400749v

4. Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, et al. A randomized trial of bio-optimized curcumin for knee osteoarthritis (Arthrocur®). *J Pain Res.* 2019;12:975–88. doi:10.2147/JPR.S195467
5. Panahi Y, Majeed M, Sahebkar A. Curcumin + piperine in metabolic syndrome: a randomized trial. *Phytother Res.* 2017;31(7):1141–9. doi:10.1002/ptr.5820
6. Rahimnia AR, Panahi Y, Karimi MH, Dadvar V, Sahebkar A. Curcumin adjunct to standard therapy in inflammatory bowel disease: short-term randomized controlled trial. *Phytother Res.* 2016;30(5):1025–31. doi:10.1002/ptr.5598
7. Javadi M, Khadem-Haghighian H, Goodarzy S, Abbasi M, Nassiri-Asl M. Nanomicelle curcumin in rheumatoid arthritis: randomized controlled trial. *Int J Rheum Dis.* 2019;22(10):1857–62. doi:10.1111/1756-185X.13688
8. Hodaei H, Adibian M, Nikpayam O, et al. Curcumin supplementation improves insulin resistance and oxidative stress in type 2 diabetes mellitus: randomized controlled trial. *Diabetol Metab Syndr.* 2019;11:41. doi:10.1186/s13098-019-0437-7
9. Mansour A, Rahimi HR, Gerami H, et al. Nanocurcumin for diabetic neuropathy: randomized controlled trial. *Nutr J.* 2025;24:115. doi:10.1186/s12937-025-01184-8
10. Bateni Z, Rahimi HR, Hedayati M, Afsharian S, et al. Nano-curcumin effects on metabolic syndrome: double-blind randomized controlled trial. *Phytother Res.* 2021;35(7):3945–53. doi:10.1002/ptr.7109
11. Madhu K, Chanda K, Saji MJ. Safety and efficacy of *Curcuma longa* extract in knee osteoarthritis: randomized controlled trial. *Inflammopharmacology.* 2013;21(2):129–36. doi:10.1007/s10787-012-0163-3
12. Ziaei R, Askari G, Moradi S, et al. Curcumin and glycemic control: meta-analysis of randomized controlled trials. *Adv Exp Med Biol.* 2021;1291:139–49. doi:10.1007/978-3-030-56153-6_8
13. Pourhabibi-Zarandi F, Rafraf M, Zayeni H, Asghari-Jafarabadi M, et al. Curcumin supplementation in women with rheumatoid arthritis: randomized controlled trial. *Phytother Res.* 2022;36(4):1797–806. doi:10.1002/ptr.7422
14. Kulkarni MP, Shakeel A, Shinde BS, Rosenbloom RA. Curcumin extract for knee osteoarthritis: placebo-controlled randomized controlled trial. *Am J Ther.* 2011;18(2):170–7. doi:10.1097/MJT.0b013e318209df49
15. Hashemzadeh K, Davoudian N, Jaafari MR, Mirfeizi Z. Nanocurcumin in knee osteoarthritis: randomized controlled trial. *Curr Rheumatol Rev.* 2020;16(2):158–64. doi:10.2174/1874471013666191223152658
16. Ezzat SM, Khairy ME, Mady FM, et al. Curcumin plus methotrexate in rheumatoid arthritis: a controlled trial. *Phytother Res.* 2019;33(5):1396–1404. doi:10.1002/ptr.6308
17. Lau ET-L, et al. Nano-curcumin adjunct to metformin in type 2 diabetes mellitus: randomized controlled trial. *BMC Complement Med Ther.* 2020;20:15. doi:10.1186/s12906-019-2801-4
18. Neta GC, et al. Piperine-enhanced *Curcuma longa* in Brazilian patients with type 2 diabetes mellitus: randomized controlled trial. *Nutr Metab Cardiovasc Dis.* 2021;31(6):1809–19. doi:10.1016/j.numecd.2021.02.004

19. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes: a randomized, double-blind, placebo-controlled trial in prediabetes. *Diabetes Care*. 2012;35(11):2121–7. doi:10.2337/dc12-0116
20. Poolsup N, Suksomboon N, Kurnianta PDM, Deawjaroen K. Effects of curcumin on glycemic control and lipid profile in prediabetes and type 2 diabetes mellitus: a systematic review and meta-analysis. *PLoS One*. 2019;14(4):e0215840. doi:10.1371/journal.pone.0215840
21. Chuengsamarn S, et al. Curcumin extract improves beta cell function and insulin sensitivity in obese T2DM patients: randomized controlled trial. *Diabetologia*. 2024;67(5):950–9. doi:10.1007/s00125-023-06190-y
22. Zhang B, Liu K, Yang H, et al. Gut microbiota: the potential key target of TCM's therapeutic effect of treating different diseases using the same method ulcerative colitis and type 2 diabetes mellitus as examples. *Front Cell Infect Microbiol*. 2022;12:855075. doi:10.3389/fcimb.2022.855075
23. Soleimani V, Sahebkar A, Hossein H. Turmeric (*Curcuma longa*) and its major constituent (curcumin) as nontoxic and safe substances: a review. *Phytother Res*. 2018;32:985–95. doi:10.1002/ptr.6054
24. Chainani-Wu N, Silverman S, Reingold A, et al. A randomized, placebo-controlled, double-blind clinical trial of curcuminoids in oral lichen planus. *Phytomedicine*. 2007;14(5):437–46. doi:10.1016/j.phymed.2007.05.006
25. Pivari F, Mingione A, Brasacchio C, Soldati L. Curcumin and type 2 diabetes mellitus: prevention and treatment. *Nutrients*. 2019;11(8):1837. doi:10.3390/nu11081837
26. Jiménez-Osorio AS, Castro-Quintero D, Tapia E, et al. Curcumin supplementation in diabetic and non-diabetic chronic kidney disease: effects on lipoperoxidation and renal function. *Clin Nutr ESPEN*. 2020;36:127–33. doi:10.1016/j.clnesp.2019.12.014
27. Jurgenka JW, et al. Nanocurcumin and rheumatoid arthritis: immunologic outcomes from double-blind randomized controlled trial. *Int J Rheum Dis*. 2019;22(10):1857–62. doi:10.1111/1756-185X.13688
28. Gu Y, Niu Q, Zhang Q, Zhao Y. Ameliorative effects of curcumin on type 2 diabetes mellitus. *Molecules*. 2024;29(12):2934. doi:10.3390/molecules29122934
29. Alsulaim AK, Almutaz TH, Albati AA, Rahmani AH. Therapeutic potential of curcumin in prevention of streptozocin-induced diabetes by modulation of oxidative stress and inflammation. *Molecules*. 2023;29(1):128. doi:10.3390/molecules29010128
30. Pathomwachaiwat T, et al. Effects of turmeric supplementation on glucose metabolism in diabetes and metabolic syndrome: an umbrella review. *PLoS One*. 2023;18(7):e0288997. doi:10.1371/journal.pone.0288997